Definitive

Vencanna Trading Halt Pending Standard CSE Change of Business

Retrieved on: 
Monday, May 2, 2022
COVID-19, Forward-looking statement, Investment, Definitive, Cannabis, Public expenditure, Contract, Committee on Capital Markets Regulation, Corporation, CSE, Partnership, Industry, Government, Publication, Health, Achievement, Market, Transaction, News, AB, Security (finance), Bank, Public relations

"Vencanna Ventures" (the "Corporation" or "Vencanna") (CSE:VENI; OTCQB: TPPRF) Vencanna has been halted by the Canadian Stock Exchange ("CSE") pursuant to previously announced signing of the definitive agreement with Cannavative Group LLC (the "Transaction").

Key Points: 
  • "Vencanna Ventures" (the "Corporation" or "Vencanna") (CSE:VENI; OTCQB: TPPRF) Vencanna has been halted by the Canadian Stock Exchange ("CSE") pursuant to previously announced signing of the definitive agreement with Cannavative Group LLC (the "Transaction").
  • The Transaction constitutes a "Fundamental Change" pursuant to the policies of the CSE, and the securities of Vencanna shall remain halted until the acceptance of the CSE and the approval of the shareholders of Vencanna regarding the Transaction.
  • It is anticipated that the Transaction will be completed the summer of 2022 at which time the halt will be lifted.
  • The transactions have transitioned the Corporation from an oil and gas issuer to a merchant capital firm, rebranded as "Vencanna Ventures".

Brascan Gold to Acquire Seven (7) Gold Properties in Newfoundland

Retrieved on: 
Wednesday, April 6, 2022
Company, Definitive, Letter, Property, Anomaly, BRAS, CEO, National instrument, Textbook, Gold, Letter of intent, Intention, Geology, Disclosure, GLOBE, News, CSE, Black cat, Uranium, Baie Verte, Brookfield Asset Management, BC

The Properties (identified in blue in the below image) cover a total of 13,125 hectares spread broadly across Newfoundland.

Key Points: 
  • The Properties (identified in blue in the below image) cover a total of 13,125 hectares spread broadly across Newfoundland.
  • Brascans current stable of five (5) gold properties are identified in gold in the below image and are focused in northern Newfoundland in the Baie Verte area.
  • Upon signing the Definitive Agreement, Brascan intends to immediately conduct field programs including drilling to expand on the gold potential of the Properties.
  • Balbir Johal, CEO and Director of Brascan, states Brascan is building a large portfolio of gold properties, carefully selected across Newfoundland.

Osisko Metals Announces Signing of an Option Agreement to Acquire Gaspé Copper Mine From Glencore Canada

Retrieved on: 
Monday, March 28, 2022
TSX Venture Exchange, Ministry of Oil and Mineral Reserves (Syria), Negotiation, CEO, Resource management, Qualified person (European Union), Time, GLOBE, Carbon nanotube supported catalyst, PEA, Definitive, Technical report, NSR, SEDAR, Hussey, Metal, Mineral resource estimation, Person, Phrase, Northern Ontario Party, Needle, Letter, Pine Point, Legislation, IRR, Copper extraction, Mount, NPV, Partnership, Company, Exercise, Mineral, Drill, Techno-economic assessment, Chief executive officer, Needle Mountain, News, Nature, Acquisition, Mining, Property management, Security (finance), Lithium, Risk management, Eastern Canada, Party, List of regions of Quebec, Porphyry Mountain, Copper, Glencore, Osisko Gold Royalties, Option

The successful closing of this transaction will give Osisko Metals shareholders significant copper exposure and make Glencore a major shareholder of the Company.

Key Points: 
  • The successful closing of this transaction will give Osisko Metals shareholders significant copper exposure and make Glencore a major shareholder of the Company.
  • The note will be convertible by Glencore into units of Osisko Metals at a price of $0.40 per unit.
  • Glencore will retain a commercially reasonable offtake for 100% of concentrates produced during the renewed life of mine at Gasp Copper.
  • Osisko Metals will pay to Glencore an additional cash consideration of US$20M upon commencement of commercial production at Gasp Copper.

reacHIRE Releases The Definitive Return-to-Work Playbook

Retrieved on: 
Wednesday, March 23, 2022
Aurora, Definitive, Family, LinkedIn, T-Mobile, Definiteness, IRobot, Woman, CEO, Workforce, Dell Technologies, Acquisition, Analog Devices, Rocket Software, Twitter, Goal, Swartz, The Wall Street Journal, GLOBE, Time, Anxiety, Wayfair, Workplace, Social media, Fidelity Investments, HR, Management, Amazon

CONCORD, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- reacHIRE , committed to supporting people returning to the workplace through returnship programs and technology solutions, today announced the launch of its new book titled The Definitive Return-to-Work Playbook .

Key Points: 
  • CONCORD, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- reacHIRE , committed to supporting people returning to the workplace through returnship programs and technology solutions, today announced the launch of its new book titled The Definitive Return-to-Work Playbook .
  • The Definitive Return-to-Work Playbook is a must-have for anyone considering a return to corporate work following a career break.
  • Not only does The Definitive Return-to-Work Playbook provide a road map back into the workforce for employees, its also an outstanding talent guide for employers.
  • To request a complimentary copy of The Definitive Return-to-Work Playbook, please contact The Devon Group.

Definitive Healthcare Launches Passport Analytics Suite

Retrieved on: 
Wednesday, March 16, 2022
Commercial, SVP, Intelligence, Solution, GLOBE, Passport, Health care, CDC, Patient, KPI, FDA, Organization, Software as a service, Environment, Promotional mix, Definitive, EMR, CEO, Epidemiology, Oxford spelling, Wiz, Industry, Bronchopulmonary segment, CMS, Marketing, Fine chemical, Computer data storage, Industrial design, Sanofi

FRAMINGHAM, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH ), an industry leader in healthcare commercial intelligence, today announced the general availability of the Passport Analytics Suite, a set of products that helps life science organizations develop, launch and commercialize products more efficiently by delivering data-agnostic analytics on-demand.

Key Points: 
  • FRAMINGHAM, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH ), an industry leader in healthcare commercial intelligence, today announced the general availability of the Passport Analytics Suite, a set of products that helps life science organizations develop, launch and commercialize products more efficiently by delivering data-agnostic analytics on-demand.
  • The Passport Analytics Suite is powered by Analytical Wizards, the company acquired by Definitive Healthcare in February 2022.
  • Comprised of two products Passport Promotional Analytics and Passport Planning & Performance the Passport Analytics Suite delivers commercial intelligence around product planning, product performance and marketing optimization.
  • However, Definitive Healthcare data is not required for a successful implementation of the Passport Analytics Suite.

Argentina Lithium Receives TSXV Approval to Acquire Rincon West and Pocitos Properties in Salta Province

Retrieved on: 
Wednesday, March 16, 2022
Lithium, Program, News, Environmental Defense v. Duke Energy Corp., TSX Venture Exchange, Multimedia, Definitive, Company, CDN, C.E.O, OTC, FSE, BC

"Now that we've received TSXV approval, we can begin our exploration and drilling program.

Key Points: 
  • "Now that we've received TSXV approval, we can begin our exploration and drilling program.
  • These properties hold exceptional lithium discovery potential,"stated Nikolaos Cacos, President and C.E.O.
  • Argentina Lithium & Energy Corp is focused on acquiring high quality lithium projects in Argentina, and advancing them towards production in order to meet the growing global demand from the battery sector.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/argentina-lithium-receives-tsxv...
    SOURCE Argentina Lithium & Energy Corp.

EnerSpar and Israeli-based Nurexone provide update on progress to Closing RTO

Retrieved on: 
Tuesday, March 15, 2022
Exosome, Traumatic brain injury, Technology, Canada Business Corporations Act, TSX Venture Exchange, Subsidiary, Mission statement, Distribution, Person, Sale, Definitive, Company, CEO, OR, Arrangers' Publishing Company, THE, Arrangement, Spinal cord injury, FSE, Issuer, Security (finance), Cryptocurrency, Technion – Israel Institute of Technology, Transaction

The Arrangement Agreement was entered into in connection with the proposed transaction (the "Proposed Transaction") involving the Company and Nurexone Biologic Ltd. ("Nurexone"), which was announced on August 30, 2021.

Key Points: 
  • The Arrangement Agreement was entered into in connection with the proposed transaction (the "Proposed Transaction") involving the Company and Nurexone Biologic Ltd. ("Nurexone"), which was announced on August 30, 2021.
  • The Arrangement is intended to divest the Company of its mineral assets as in connection with the Proposed Transaction with Nurexone, an Israeli pharmaceutical corporation.
  • In addition, the Company and Nurexone are pleased to announce that they are progressing towards completing the previously announced Proposed Transaction.
  • The effect of this is that the existing Enerspar business will continue for the sole benefit of the existing EnerSpar shareholders.

Applied DNA Executes LOI with Spindle Biotech for Research Collaboration on Simplified High Yield mRNA Production System

Retrieved on: 
Monday, March 14, 2022
Medical Supplies, Health, Genetics, Other Science, Research, Science, Biotechnology, IVT, NASDAQ, Energy Independence and Security Act of 2007, Textile, Private Securities Litigation Reform Act, Twitter, Cannabis, RNA transfection, Securities Act of 1933, PCR, COVID-19 testing, United States Department of Agriculture, Company, Enzyme, Russell, Infection, Research, Therapy, FDA, LinkedIn, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, Cancer, Plasmid, Completion, Securities Exchange Act of 1934, DNA, Forward-looking statement, USDA, United States Department of State, TCR, Technology, COVID-19, Definitive, SEC, Food, History, RNA, CRISPR, CEO, Vaccine, Applied DNA Sciences, Spindle, Applied DNA Sciences, Spindle Biotech Inc., APPLIED DNA SCIENCES, SPINDLE BIOTECH INC.

The companies believe the combination of their respective platforms provides for a simplified, high yield, and 100% cell-free workflow that is differentiated from current mRNA production that uses plasmid DNA (pDNA).

Key Points: 
  • The companies believe the combination of their respective platforms provides for a simplified, high yield, and 100% cell-free workflow that is differentiated from current mRNA production that uses plasmid DNA (pDNA).
  • Under the proposed Definitive Agreement terms, Applied DNA will produce specialized IVT DNA templates for RNA transcription using Spindle Biotechs RNA polymerase.
  • Following initial validation work, the companies intend to explore the commercialization of an mRNA production system that leverages the benefits of the companies respective platforms.
  • Applied DNA is commercializing LinearDNA, its proprietary, large-scale polymerase chain reaction ("PCR")-based manufacturing platform that allows for the large-scale cell-free production of specific DNA sequences.

MAG Silver to Acquire Gatling Exploration

Retrieved on: 
Friday, March 11, 2022
Canada Business Corporations Act, Toronto Stock Exchange, Gold, Consideration, OTCQB, Nature, Disclosure, Deer, Fresnillo, McVittie, VWAP, Larder, Fresnillo plc, GLOBE, TSX, SEC, CEO, Project, Risk, Consultant, Definitive, Forward-looking statement, Arrangement, MAG, NYSE American, Deer Trail, Colorado, Cadillac, NYSE, COVID-19, Transaction, Silver, Engineering, Security (finance), Mining, Gatling gun

VANCOUVER, British Columbia, March 11, 2022 (GLOBE NEWSWIRE) -- MAG Silver Corp. (TSX / NYSE American: MAG) (MAG or MAG Silver) is pleased to announce that it has entered into a Definitive Arrangement Agreement (the Definitive Agreement) with Gatling Exploration Inc. (TSXV: GTR, OTCQB: GATGF) (Gatling) pursuant to which MAG will acquire all of the issued and outstanding common shares of Gatling (the Transaction) in an all-share transaction.

Key Points: 
  • VANCOUVER, British Columbia, March 11, 2022 (GLOBE NEWSWIRE) -- MAG Silver Corp. (TSX / NYSE American: MAG) (MAG or MAG Silver) is pleased to announce that it has entered into a Definitive Arrangement Agreement (the Definitive Agreement) with Gatling Exploration Inc. (TSXV: GTR, OTCQB: GATGF) (Gatling) pursuant to which MAG will acquire all of the issued and outstanding common shares of Gatling (the Transaction) in an all-share transaction.
  • Each Gatling shareholder will be entitled to receive 0.01702627 (the Exchange Ratio) of a common share of MAG for each share of Gatling held (the Consideration).
  • The Definitive Agreement provides for a C$1.0 million termination fee payable by Gatling to MAG in certain circumstances or an expense reimbursement fee of C$600,000 payable by Gatling to MAG under certain circumstances.
  • MAG and Gatling have also entered into a loan agreement pursuant to which MAG has agreed to provide Gatling with a C$3 million secured convertible bridge loan to finance Gatlings accounts payable and operating expenses, with all such payments subject to the prior approval of MAG.

Acerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva™

Retrieved on: 
Monday, February 28, 2022
Risk, Prescription, Government, SEDAR, Failure, Ministry, COVID-19, Hypogonadism, Company, Urology, Woman, Nocturia, Sidley Austin, MFDS, TSX, Therapy, Board of directors, Board, Growth, Man, Common, Sale, Safety, Terminology, Definitive, Quality of life, Policy, Regulation of tobacco by the U.S. Food and Drug Administration, Acquisition, Twitter, FAQ, Testosterone, LinkedIn, Testosterone (medication), Indian stock exchange, ASP, OTCQB, Sleep, Patient, GLOBE, Health, Calendar, Ministry of Food and Drug Safety, Health Canada, FDA, Marketing, Time, Pharmaceutical industry, Life insurance, Security (finance), Risk management, Management, Pristimantis acerus, Food, Director, Serenity

TORONTO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into a definitive agreement (the “Definitive Agreement”) to indirectly acquire Serenity LLC (“Serenity”) and the global rights to its Noctiva brand in a combined cash and stock transaction. Serenity, based in Miami, FL, is a specialty pharmaceutical company, focused on developing therapies for diseases associated with voiding disorders, and had previously been granted approval by the U.S. Food and Drug Administration (FDA) for its Noctiva (desmopressin acetate) nasal spray. Noctiva is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void.1 It is the first FDA-approved therapy for nocturia.

Key Points: 
  • Acerus portfolio will include two FDA-approved products, Noctiva and Natesto, that address large patient populations as well as a pipeline of future opportunities related to Noctiva.
  • The combination of Serenity with the Acerus business further increases our footprint in attractive urology and mens health market segments.
  • Torreya Capital LLC served as exclusive financial advisor to Acerus and provided a fairness opinion to Acerus Board of Directors.
  • All of the Serenity securityholders are arms-length to Acerus and none of Acerus directors or officers are insiders of Serenity.